Results 11 to 20 of about 20,614 (289)

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure
There is a need to address the evidence gap regarding the in‐hospital administration of sacubitril/valsartan in acute myocardial infarction patients.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
doaj   +2 more sources

Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial. [PDF]

Nat Commun
Diffuse interstitial fibrosis is associated with adverse outcomes in hypertensive heart disease and may be reversible. Sacubitril/valsartan could offer greater anti-fibrotic effects than valsartan alone.
Lee V, Dalakoti M, Zheng Q, Toh DF, Boubertakh R, Bryant JA, Aw TC, Lee CH, Richards AM, Butler J, Díez J, Foo R, Cook SA, Lam CS, Le TT, Chin CW.   +15 more
europepmc   +2 more sources

Sacubitril-Valsartan

Reactions Weekly
Patel P, Nicolas D, Reed M.
europepmc   +8 more sources

Prescription Patterns of Sacubitril/Valsartan in an Outpatient Population Diagnosed with Heart Failure with Reduced Ejection Fraction After a Recent Hospitalization. [PDF]

Epidemiologia (Basel)
Background: Sacubitril/Valsartan is a first-line treatment for heart failure with reduced ejection fraction (HFrEF) according to international guidelines.
Roustan D, Bothorel H, Kherad O.
europepmc   +2 more sources

Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan

JACC: Heart Failure, 2020
Pardeep S Jhund, Pooja Dewan, Piotr Ponikowski   +2 more
exaly   +2 more sources

Combining Neprilysin Inhibitor With AT2R Agonist Is Superior to Combination With AT1R Blocker in Providing Reno-Protection in Obese Rats

Frontiers in Pharmacology, 2022
Clinical use of the combination therapy of the neprilysin inhibitor sacubitril and angiotensin II type 1 receptor blocker valsartan is known to be associated with albuminuria.
Elizabeth Alana Gray, Sanket N. Patel, Peter A. Doris, Tahir Hussain   +3 more
doaj   +1 more source

Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction

Frontiers in Cardiovascular Medicine, 2023
IntroductionIn 2014, the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that sacubitril/valsartan can reduce the risk of hospitalization and death from ...
Pei Yang, Pei Yang, Xiaokang Li, Lijin Wang, Xinlei Wu, Chiyao Wang, Tian Li, Haiyan Wang   +7 more
doaj   +1 more source

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice

Frontiers in Endocrinology, 2022
Treatment of heart failure with the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan improved glycemic control in individuals with type 2 diabetes. The relative contribution of neprilysin inhibition versus angiotensin II receptor antagonism
Nathalie Esser, Nathalie Esser, Nathalie Esser, Christine Schmidt, Breanne M. Barrow, Laura Cronic, Daryl J. Hackney, Stephen M. Mongovin, Meghan F. Hogan, Meghan F. Hogan, Andrew T. Templin, Andrew T. Templin, Joseph J. Castillo, Joseph J. Castillo, Rebecca L. Hull, Rebecca L. Hull, Sakeneh Zraika, Sakeneh Zraika   +17 more
doaj   +1 more source

Bradykinin-Mediated Angioedema Induced by Commonly Used Cardiovascular Drugs

Drugs and Drug Candidates, 2023
ACE inhibitors, sartans, and sacubitril are among the most important drugs for the prevention of cardiovascular mortality and morbidity. At the same time, they are known to cause non-allergic bradykinin-mediated angioedema, a potentially fatal swelling ...
Janina Hahn, Jens Greve, Murat Bas, Georg Kojda   +3 more
doaj   +1 more source

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies

Journal of Cardiovascular Development and Disease, 2022
Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the ...
Hisham A. Badreldin, Nasser Aldosari, Lama Alnashwan, Taif Almutairi, Nada Yousif, Khalid Alsulaiman, Ohoud Aljuhani, Awatif Hafiz, Omar Alshaya   +8 more
doaj   +1 more source